Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC ferric carboxymaltose Iron deficiency anemia Pending
TBC rozanolixizumab Generalized myasthenia gravis (gMG). Pending
TBC talquetamab Relapsed or refractory multiple myeloma Pending
TBC etonogestrel Prevention of pregnancy Withdrawn
TBC filgotinib Arthritis, Rheumatoid Withdrawn
TBC zilucoplan Generalized myasthenia gravis (gMG) Active
TBC ivosidenib Acute myeloid leukemia (AML) Received
TBC danicopan Paroxysmal nocturnal hemoglobinuria (PNH) Pending
TBC sotatercept Pulmonary arterial hypertension (WHO group 1) Pending
TBC eplontersen Polyneuropathy in hereditary transthyretin-mediated amyloidosis Pending